Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns

被引:7
|
作者
Mosquera Orgueira, Adrian [1 ,2 ,3 ]
Antelo Rodriguez, Beatriz [1 ,2 ,3 ]
Alonso Vence, Natalia [1 ,2 ]
Bendana Lopez, Angeles [1 ,2 ]
Diaz Arias, Jose Angel [1 ,2 ]
Diaz Varela, Nicolas [2 ]
Gonzalez Perez, Marta Sonia [1 ,2 ]
Perez Encinas, Manuel Mateo [1 ,3 ]
Bello Lopez, Jose Luis [1 ,2 ,3 ]
机构
[1] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain
[2] Complexo Hosp Univ Santiago de Compostela, Div Hematol, SERGAS, Santiago De Compostela, Spain
[3] Univ Santiago de Compostela, Dept Med, Santiago De Compostela, Spain
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
日本学术振兴会;
关键词
chronic lymphocytic leukemia; time to treatment prediction; gene expression; RNAseq; machine learning; prognostic factors; IGHV; LYMPHOMA;
D O I
10.3389/fonc.2019.00079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the International Cancer Genome Consortium CLL cohort to determine new gene expression patterns that correlate with clinical evolution.We determined that a 290-gene expression signature, in addition to immunoglobulin heavy chain variable region (IGHV) mutation status, stratifies patients into four groups with notably different time to first treatment. This finding was confirmed in an independent cohort. Similarly, we present a machine learning algorithm that predicts the need for treatment within the first 5 years following diagnosis using expression data from 2,198 genes. This predictor achieved 90% precision and 89% accuracy when classifying independent CLL cases. Our findings indicate that CLL progression risk largely correlates with particular transcriptomic patterns and paves the way for the identification of high-risk patients who might benefit from prompt therapy following diagnosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] EXPRESSION OF FCGAMMARIIB PREDICTS TIME TO TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Bosch, R.
    Vicente, E. P.
    Mora, A.
    Ferrer, G.
    Damle, R.
    Gorlatov, S.
    Rai, K.
    Montserrat, E.
    Nomdedeu, J.
    Blanco, L.
    Pratcorona, M.
    Delgado, J.
    Sierra, J.
    Chiorazzi, N.
    Moreno, C.
    HAEMATOLOGICA, 2016, 101 : 427 - 428
  • [42] Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia
    Wierda, William G.
    O'Brien, Susan
    Wang, Xuemei
    Faderl, Stefan
    Ferrajoli, Alessandra
    Do, Kim-Anh
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Thomas, Deborah
    Koller, Charles A.
    Burger, Jan A.
    Lerner, Susan
    Schlette, Ellen
    Abruzzo, Lynne
    Kantarjian, Hagop M.
    Keating, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4088 - 4095
  • [43] Real-world treatment patterns and characteristics in patients with chronic lymphocytic leukemia
    Schenkel, Brad
    Rider, Alex
    Macomson, Brian
    Hallworth, Pam
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
  • [44] Characteristics and treatment patterns in patients newly diagnosed with chronic lymphocytic leukemia (CLL).
    Hess, G. P.
    Chen, C.
    Satram-Hoang, S.
    Reyes, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Treatment patterns of newly diagnosed chronic lymphocytic leukemia (CLL) patients in the US
    Wang, Song
    Schenkel, Brad
    Wallace, Anna
    Chen, Yen Wen
    York, Whitney
    LEUKEMIA & LYMPHOMA, 2017, 58 : 87 - 87
  • [46] Current Treatment of Chronic Lymphocytic Leukemia
    Krzysztof Jamroziak
    Bartosz Puła
    Jan Walewski
    Current Treatment Options in Oncology, 2017, 18
  • [47] Ofatumumab for the treatment of chronic lymphocytic leukemia
    Grosicki, Sebastian
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (03) : 265 - 272
  • [48] Bendamustine in the treatment of chronic lymphocytic leukemia
    Ujjani, Chaitra
    Cheson, Bruce D.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 617 - 623
  • [49] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Eradat, Herbert
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (05) : 469 - 476
  • [50] Current Treatment of Chronic Lymphocytic Leukemia
    Jamroziak, Krzysztof
    Pula, Bartosz
    Walewski, Jan
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)